Saturday, May 4, 2024
ADVT 
International

Pfizer confirms COVID pill's results, potency versus omicron

Darpan News Desk The Canadian Press, 14 Dec, 2021 11:01 AM
  • Pfizer confirms COVID pill's results, potency versus omicron

Pfizer said Tuesday that its experimental pill to treat COVID-19 appears effective against the omicron variant.

The company also said full results of its 2,250-person study confirmed the pill's promising early results against the virus: The drug reduced combined hospitalizations and deaths by about 89% among high-risk adults when taken shortly after initial COVID-19 symptoms.

Separate laboratory testing shows the drug retains its potency against the omicron variant, the company announced, as many experts had predicted. Pfizer tested the antiviral drug against a man-made version of a key protein that omicron uses to reproduce itself.

The updates come as COVID-19 cases, deaths and hospitalization are all rising again and the U.S. hovers around 800,000 pandemic deaths. The latest surge, driven by the delta variant, is accelerating due to colder weather and more indoor gatherings, even as health officials brace for the impact of the emerging omicron mutant.

The Food and Drug Administration is expected to soon rule on whether to authorize Pfizer’s pill and a competing pill from Merck, which was submitted to regulators several weeks earlier. If granted, the pills would be the first COVID-19 treatments that Americans could pickup at a pharmacy and take at home.

Pfizer’s data could help reassure regulators of its drug's benefit after Merck disclosed smaller-than-expected benefits for its drug in final testing. Late last month, Merck said that its pill reduced hospitalizations and deaths by 30% in high-risk adults.

Both companies initially studied their drugs in unvaccinated adults who face the gravest risks from COVID-19, due to older age or health problems, such as asthma or obesity.

Pfizer is also studying its pill in lower-risk adults — including a subset who are vaccinated — but reported mixed data for that group on Tuesday.

In interim results, Pfizer said its drug failed to meet its main study goal: sustained relief from COVID-19 for four days during or after treatment, as reported by patients. But the drug did achieve a second goal by reducing hospitalizations by about 70% among that group, which included otherwise healthy unvaccinated adults and vaccinated adults with one or more health issues. Less than 1% of patients who got the drug were hospitalized, compared with 2.4% of patients who got a dummy pill.

An independent board of medical experts reviewed the data and recommended Pfizer continue the study to get the full results before proceeding further with regulators.

Across both of Pfizer’s studies, adults taking the company's drug had a 10-fold decrease in virus levels compared with those on placebo.

The prospect of new pills to fight COVID-19 can’t come soon enough for communities in the Northeast and Midwest, where many hospitals are once again being overloaded by incoming virus cases.

Both the Merck and Pfizer pills are expected to perform well against omicron because they don’t target the coronavirus’ spike protein, which contains most of the new variant’s mutations.

Centers for Disease Control and Prevention Director Rochelle Walensky, appearing on NBC’s “Today” on Tuesday, said the best way for people to protect themselves against COVID-19 is to get vaccinated and get a booster shot. She said the Pfizer pill, if authorized by the FDA, “will be another great tool, but we need to diagnose people early.”

The U.S. government has agreed to purchase enough of Pfizer’s drug to treat 10 million people and enough of Merck’s to treat 3 million, pending FDA authorization.

MORE International ARTICLES

EXPLAINER: What is this new COVID variant in South Africa?

EXPLAINER: What is this new COVID variant in South Africa?
Maybe. As of noon Friday, travelers arriving in the U.K. from South Africa, Namibia, Botswana, Lesotho, Eswatini and Zimbabwe will have to self-isolate for 10 days. European Union nations also moved quickly on Friday to try to stop air travel from southern Africa.

EXPLAINER: What is this new COVID variant in South Africa?

Telangana youth dies in road accident in US

Telangana youth dies in road accident in US
His family has appealed to the Indian government to help in bringing his body home. According to delayed information reaching his family members, Mandali Shekhar (28) died when a speeding car hit him at Ellicott City in Maryland state on November 19.

Telangana youth dies in road accident in US

5 dead after vehicle rams into US city parade

5 dead after vehicle rams into US city parade
At least five people were killed and more than 40 others injured after a vehicle rammed into a crowd at an annual holiday parade in Waukesha, a city in the US state of Wisconsin, authorities said on Monday.

5 dead after vehicle rams into US city parade

Head Granthi at Kabul's Gurdwara Karte Parwan among 2 evacuated from Af

Head Granthi at Kabul's Gurdwara Karte Parwan among 2 evacuated from Af
Satveer Singh, an Indian citizen serving as Head Granthi at Gurdwara Karte Parwan, Kabul, for the past twenty one years and Sorjit Singh, Afghan Citizen hailing from Khost Province and caretaker of Gurdwara situated there, were evacuated on Thursday.

Head Granthi at Kabul's Gurdwara Karte Parwan among 2 evacuated from Af

1 killed, 6 injured in gas cylinder blast in Pakistan's Karachi

1 killed, 6 injured in gas cylinder blast in Pakistan's Karachi
The incident happened inside a multi-storeyed building in Lyari area of Karachi, the provincial capital of southern Sindh province, police officials told local media.

1 killed, 6 injured in gas cylinder blast in Pakistan's Karachi

WHO: Europe is only region with increasing COVID deaths

WHO: Europe is only region with increasing COVID deaths
 The World Health Organization says coronavirus deaths in Europe rose 5% in the last week, making it the only region in the world where COVID-19 deaths increased. The U.N. health agency said confirmed cases jumped 6% globally, driven by increases in the Americas, Europe and Asia.

WHO: Europe is only region with increasing COVID deaths